Drug Information

Drug General Information
Drug ID
D06JAL
Former ID
DIB000476
Drug Name
8H9
Drug Type
Antibody
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 1 [522998]
Company
Memorial Sloan-Kettering Cancer Center
Target and Pathway
Target(s) Tenascin Target Info [526968]
KEGG Pathway PI3K-Akt signaling pathway
Focal adhesion
ECM-receptor interaction
MicroRNAs in cancer
NetPath Pathway IL4 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
Pathway Interaction Database Beta1 integrin cell surface interactions
Beta3 integrin cell surface interactions
Alpha9 beta1 integrin signaling events
Syndecan-4-mediated signaling events
Reactome Integrin cell surface interactions
Syndecan interactions
ECM proteoglycans
WikiPathways TGF beta Signaling Pathway
Focal Adhesion
Syndecan interactions
Extracellular matrix organization
Integrin cell surface interactions
References
Ref 522998ClinicalTrials.gov (NCT01099644) Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum. U.S. NationalInstitutes of Health.
Ref 526968In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res. 2004 Feb 15;64(4):1419-24.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.